ORG – Page 266 – Talk Bio

Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program

1 year ago talkbio0Tagged Angioedemas, Hereditary, Collaboration, Editas Medicine, KalVista, Myers, Partnership, preclinical program, squibb, T cell therapy

Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.

Federal Trade Commission Challenges Novo Nordisk’s Ozempic and Over 300 ‘Junk’ Patent Listings in FDA Database

1 year ago talkbio0Tagged Drug Development, Drug Industry, heroin, Intellectual Property, Legal patent, Nordisk, Ozempic, United States Federal Trade Commission, United States Food and Drug Administration

FTC, Novo Nordisk, Ozempic, FDA, patent listings, crackdown, junk patents, pharmaceutical industry, intellectual property, drug development.

Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity

1 year ago talkbio0Tagged Capacity, Drug Industry, drug manufacturing, Eli Lilly, financial outlook, Mounjaro, production, Zepbound

Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.

Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics

1 year ago talkbio0Tagged Acquisition (action), CDK-like kinase inhibitors, Collaboration, development aspects, Epygenix, genetic epilepsies, Harmony Pharmaceuticals, Infantile Severe Myoclonic Epilepsy, Mutation, research

Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors

Enlaza Secures $100M for Groundbreaking Irreversible Protein Binding Technology

1 year ago talkbio0Tagged Biotechnology, Drug Development, Enlaza, Investments, irreversible, Medical Research activity, Protein Binding

Enlaza, funding, investment, protein binding, irreversible, biotechnology, medical research, drug development, therapeutics.

Prime Medicine Secures FDA Approval for Pioneering Gene Editing Therapy Trial

1 year ago talkbio0Tagged Approved, Clinical Trials, Gene Modification, Hereditary Diseases, Prime Medicine, United States Food and Drug Administration

Prime Medicine, FDA approval, gene editing, clinical trial, innovative therapy, genetic diseases

FDA Approval Milestones: X4 Pharmaceuticals, Pfizer, and Genmab Secure Nods for Rare Disease and Cervical Cancer Treatments

1 year ago talkbio0Tagged Biotechnology, Drug Approval, Genmab, Health care facility, Malignant tumor of cervix, Pfizer, United States Food and Drug Administration

FDA, X4 Pharmaceuticals, Pfizer, Genmab, rare disease, cervical cancer, drug approval, treatment, healthcare, biotechnology.

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

1 year ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.